Knight Therapeutics Inc. (KHTRF) Stock

About Knight Therapeutics Inc.

Knight Therapeutics Inc. operates as a specialized pharmaceutical enterprise, actively engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of a broad spectrum of pharmaceutical goods, consumer health solutions, and medical devices. Its operational footprint extends across Canada, Latin America, and other global markets. The company's extensive product offerings encompass treatments like Nerlynx, targeting extended adjuvant and metastatic breast cancer; Tafasitamab, prescribed for relapsed or refractory diffuse large B-cell lymphoma; and Pemigatinib, designed for metastatic cholangiocarcinoma. It also provides Trelstar for advanced prostate cancer and endometriosis-related pain; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima, utilized for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. Further expanding its therapeutic array, Knight Therapeutics supplies Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma. Other notable products include Zyvalix and Leprid, both aimed at metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Rembre for chronic myeloid leukemia; Ambisome and Cresemba, crucial for managing fungal infections; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for irritable bowel syndrome with constipation. The company's portfolio additionally features Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; and Bijuva for moderate to severe menopausal vasomotor symptoms in women with intact uteri. Rounding out its specialized treatments are Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for Pseudomonas aeruginosa lung infections in cystic fibrosis patients; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Beyond its core product activities, Knight Therapeutics Inc. also serves as a financier for other life science companies and allocates capital to life sciences venture capital funds. The organization was incorporated in 2013 and maintains its corporate headquarters in Montreal, Canada.

Knight Therapeutics Inc. is headquartered in CA.

Knight Therapeutics Inc. (KHTRF) stock trades at $6.85 with a market capitalization of $672.33M. The stock is valued at a price-to-earnings (P/E) ratio of 64.58, price-to-book of 1.17, price-to-sales of 1.70. Over the past 52 weeks the stock has ranged between $4.07 and $7.40, and currently trades 7.4% below its 52-week high.

On profitability, Knight Therapeutics Inc. generates a return on equity (ROE) of 1.91%, return on capital employed of 3.06%, an operating margin of 4.82%, a net profit margin of 2.72%.

Official website: www.gud-knight.com